Special effect apparatus
    2.
    发明授权
    Special effect apparatus 失效
    特效仪器

    公开(公告)号:US5166796A

    公开(公告)日:1992-11-24

    申请号:US796377

    申请日:1991-11-22

    CPC分类号: H04N5/2622 H04N9/74

    摘要: A special effect apparatus temporally enlarges an input video signal so as to reduce edge intrusion caused by a type of special effect processing and to eliminate color fading due to different sampling frequencies for the luminance and chrominance components of a video signal. The temporally enlarged video signal is formed by sequential selection among three signals: a reference video signal, a preceding video signal which temporally leads the reference video signal and a trailing video signal which temporally lags the reference video signal. Portions of the preceding and trailing video signals are appended to the reference video signal to produce the temporally enlarged video signal which can be processed to create a special effect devoid of edge intrusion.

    摘要翻译: 特殊效果装置时间上放大输入视频信号,以便减少由一种特殊效果处理引起的边缘入侵,并消除由于视频信号的亮度和色度分量的不同采样频率引起的色彩衰减。 时间放大的视频信号通过三个信号之间的顺序选择形成:参考视频信号,在时间上引导参考视频信号的先前视频信号和在时间上落在参考视频信号上的尾部视频信号。 将前一和后期视频信号的一部分附加到参考视频信号以产生可被处理以产生没有边缘入侵的特殊效果的时间放大的视频信号。

    Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and
corresponding -(1',3' thiazolines)
    4.
    发明授权
    Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines) 失效
    某些1-甲基 - 哌啶-4-螺-4' - (1'-3'-恶唑啉)和相应的 - (1',3'噻唑啉)

    公开(公告)号:US5407938A

    公开(公告)日:1995-04-18

    申请号:US137690

    申请日:1993-10-14

    摘要: The invention relates to compounds (I) for treating diseases of the central and peripheral nervous system, including enantiomers, racemates and acid addition and quaternary salts, ##STR1## wherein Q is selected from two H atoms, (CH.sub.2).sub.m and C(CH.sub.3).sub.2 where m is 1, 2 or 3 and n and p are; each independently 0, 1, 2 or 3, provided that n+p=1-3, and R.sup.0 is H, methyl or OH; the moiety ##STR2## R is selected from H, NH.sub.2, NH-C.sub.1-6 -alkyl, N(C.sub.1-6 -alkyl).sub.2, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl, C.sub.2-6 -alkynyl, C.sub.3-7 - cycloalkyl, C.sub.1-6 -alkyl substituted by 1-6 halogen atoms, hydroxy- C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, C.sub.1-6 -alkoxy-C.sub.1-6 -alkyl, carboxy-C.sub.1-6 -alkyl, (C.sub.1-6 -alkoxy)carbonyl-C.sub.1-6 -alkyl, amino-C.sub.1-6 -alkyl, mono-(C.sub.1-6 -alkyl)amino-C.sub.1-6 -alkyl, di-(C.sub.1-6 -alkyl)amino-C.sub.1-6 -alkyl, 2-oxo-pyrrolidin-1-yl-methyl, aryl, diarylmethylol, and C.sub.1-6 -alkyl substituted by one or two aryl groups; R' is independently selected from the group from which R is selected and C.sub.1-6 -alkanoyl and arylcarbonyl; and aryl denotes unsubstituted phenyl or phenyl substituted by 1-3 substituents selected from halogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy and CF.sub.3, subject to certain provisos.

    摘要翻译: 本发明涉及用于治疗中枢和周围神经系统疾病的化合物(I),包括对映体,外消旋体和酸加成和季盐。其中Q选自两个H原子,(CH 2)m和 C(CH 3)2,其中m为1,2或3,n和p为 每个独立地为0,1,2或3,条件是n + p = 1-3,R 0为H,甲基或OH; R 1选自H,NH 2,NH-C 1-6 - 烷基,N(C 1-6 - 烷基)2,C 1-6 - 烷基,C 2-6 - 烯基,C 2-6 - 炔基,C 3 -7-环烷基,被1-6个卤素原子取代的C 1-6 - 烷基,羟基-C 1-6 - 烷基,C 1-6 - 烷氧基,C 1-6 - 烷硫基,C 1-6 - 烷氧基-C 1-6 - 烷基, 羧基-C 1-6 - 烷基,(C 1-6 - 烷氧基)羰基-C 1-6 - 烷基,氨基-C 1-6 - 烷基,单 - (C 1-6 - 烷基)氨基-C 1-6 - 烷基, (C 1-6 - 烷基)氨基-C 1-6 - 烷基,2-氧代 - 吡咯烷-1-基 - 甲基,芳基,二芳基羟甲基和被一个或两个芳基取代的C 1-6 - 烷基; R'独立地选自选自R的基团和C 1-6 - 烷酰基和芳基羰基; 并且芳基表示未取代的苯基或被1-3个选自卤素,C 1-6 - 烷基,C 1-6 - 烷氧基和CF 3的取代基取代的苯基,具有一定条件。

    Oxathiolanes
    7.
    发明授权
    Oxathiolanes 失效
    硫辛酸

    公开(公告)号:US4876260A

    公开(公告)日:1989-10-24

    申请号:US189210

    申请日:1988-05-02

    CPC分类号: C07D497/20

    摘要: The present invention accordingly provides in one aspect, novel spiro-oxathiolane/quinuclidine compounds corresponding with the schematic structural formula (I) ##STR1## and geometrical isomers, enantiomers, diastereoisomers, racemates and acid addition salts thereof, wherein one of Y and Z is 0 and the other is S(.dbd.O).sub.n ; n is 0, 1 or 2; R' and R" are each selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, C.sub.3-7 cycloalkyl, aryl, diarylmethylol, and alkyl substituted by at least one aryl group, provided that at least R' and R" is other than hydrogen; and each X is hydrogen, or when Y is 0 and Z is S(.dbd.O).sub.n simultaneously, then each X may also be selected from the group consisting of deuterium and tritium, and provided further that when each X is hydrogen, Y is 0 and Z is S simultaneously, then at least one of R' and R" is selected from the group consisting of alkenyl, alkynyl, cyclopropyl, cyclobutyl, cycloheptyl, hydroxyalkyl and aminoalkyl.

    Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3')quiniclidine hydrochloride
    8.
    发明申请
    Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3')quiniclidine hydrochloride 失效
    顺式-2-甲基螺(1,3-氧硫杂环戊烷-5,3')奎宁啶盐酸盐的制备和纯化方法

    公开(公告)号:US20090182146A1

    公开(公告)日:2009-07-16

    申请号:US12007394

    申请日:2008-01-10

    IPC分类号: C07D497/20

    CPC分类号: C07D497/20

    摘要: An industrially acceptable process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine from a cisitrans mixture of isomers. Treatment of the mixture with an organic sulfonice acid generates a less soluble acid addition salt that is enriched in the cis-isomer. Recrystallization or pulping using various organic solvents allows for enrichment of the cis-isomer by filtration. These new sulfonic acid salts of the cis-isomer of 2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine prepared according to the present invention could be further converted into the hydrochloride salt by any known procedures such as treatment with a base and then hydrochloric acid salt formation or exchange of the sulfonic acid salt with hydrochloric acid.

    摘要翻译: 从异构体的顺式异构体混合物制备和纯化顺式-2-甲基螺(1,3-氧硫杂环戊烷-5,3')奎宁啶的工业上可接受的方法。 用有机磺酸处理混合物产生富含顺式异构体的较不溶性的酸加成盐。 使用各种有机溶剂的重结晶或制浆允许通过过滤富集顺式异构体。 根据本发明制备的2-甲基螺旋(1,3-氧硫杂环戊烷-5,3')奎宁啶的顺式异构体的这些新的磺酸盐可以通过任何已知的方法进一步转化成盐酸盐,例如用 碱,然后与盐酸形成盐酸盐或与盐酸交换磺酸盐。